TAIPEI and SAN DIEGO , Nov. 1, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug de...


    

    
	
    




	
	
	
	
	
	
	
		
		
			
			
				
 
  
    
    
    
    
    
          
		  
          
            
            
            ,  /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced the appointment of Dr. Yiu-Lian Fong to the board of directors for Ding Li Development Ltd.  Dr. Fong, a present member of the Bio Taiwan Committee (BTC) under the Executive Yuan since 2020, has served various organizations in Taiwan including the BTC, the Ministry of Science and Technology Council, and the Medical Device Innovation Center, NCKU as an expert consultant since 2017 to help drive the growth of Biotech industry. Dr. Fong previously served as the Global Head, Diagnostic Innovation and R&D and Clinical Biomarker Strategy and Development at Janssen, Johnson & Johnson. Having nearly thirty years of successful R&D leadership experience for new drug discovery and development in the global pharmaceutical companies, Dr. Fong is dedicated to addressing unmet medical needs for major diseases such as cancer. Her versatile experiences will provide valuable insights into Senhwa's strategic approaches to developing new drugs, help accelerate development timelines, and position Senhwa for the global market.
Dr. Fong received her PhD at Vanderbilt University and completed her post-doctoral training at the Johns Hopkins University. She held important and progressive leadership positions in various global pharmaceutical and IVD companies. She advanced from scientist to the Director of R&D for Novartis Vaccine and Drug Development, and subsequently to the Executive Director at the Novartis Molecular Diagnostics and the Novartis Oncology Division for Drug and Companion Diagnostic co-development. Following her role as Vice President of R&D in Abbott's Molecular Diagnostic Division, she joined Janssen Pharmaceuticals to assume global R&D leadership roles including the Global Head of Diagnostic Innovation, R&D, and CLIA Lab Operation, and the Global Head of Clinical Biomarker and Diagnostic Strategy and Development to help drive the development of precision medicines. Over her 28-year career, Dr. Fong has not only successfully led/directed numerous important R&D programs from pre-clinical, phase I-III to regulatory approval, but also supported phase-IV post-approval studies to accelerate global market expansions. Furthermore, Dr. Fong has demonstrated her expertise in strategic planning for global partnerships and global market penetration for pharmaceuticals and IVD (companion) diagnostics. Her professional expertise and experience in the biotech/pharma/IVD industry will contribute significantly to Senhwa's efforts in progressing the R&D pipeline, and facilitate the global partnerships and commercial success.
SOURCE Senhwa Biosciences, Inc.





        
            WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

        
        
            
        
            
        
            
        
            
        
            
        
            
        
            
        
            
                
                    
                        
                        
                        
                            440k+
Newsrooms &
Influencers
                        
                    
                
                    
                        
                        
                        
                            9k+
Digital Media
Outlets
                        
                    
                
                    
                        
                        
                        
                            270k+
Journalists
Opted In
                        
                    
                
            
        
        
    
          
        

  
  
  
  

    
      
    
          
	Also from this source
	
		
			
				
									
										

										
									
								
			
				
									
										

										
									
								
			
		
		
	

        
  
  
  
  
  
  

			
			
			
		
		
	

  

Senhwa Biosciences Announces the Appointment of Dr. Yiu-Lian Fong, the Former Global Head of Janssen Diagnostic Innovation and R&D at Johnson & Johnson as the New Corporate Director

Dr. Yiu-Lian Fong appointed to Senhwa Biosciences board.
Fong previously led R&D at Janssen, a Johnson & Johnson company.
Her experience in drug development may impact JNJ indirectly.
Senhwa aims to accelerate drug development with Fong's expertise.

senhwa-biosciences-announces-the-appointment-of-dr-yiu-lian-fong-the-former-global-head-of-janssen-diagnostic-innovation-and-r-d-at-johnson-johnson-as-the-new-corporate-director

Senhwa Biosciences Announces the Appointment of Dr. Yiu-Lian Fong, the Former Global Head of Janssen Diagnostic Innovation and R&D at Johnson & Johnson as the New Corporate Director

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News